GlassScriptPhysician profile
Sylvia D Noble
NPI 1790770394
$3,489.52
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $423 · 2021: $843 · 2022: $724 · 2023: $788 · 2024: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932 · Education: $17.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.24 |
| Education | $17.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $558.18 | 2019-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $342.13 | 2020-2023 | Jynarque |
| Fresenius USA Marketing, INC. | $309.52 | 2019-2023 | Velphoro, Korsuva |
| Akebia Therapeutics INC | $306.83 | 2019-2024 | Auryxia, Vafseo |
| Glaxosmithkline, LLC. | $267.06 | 2021-2023 | Benlysta |
| Vifor Pharma, INC. | $242.68 | 2019-2022 | |
| Amgen INC. | $231.76 | 2019-2024 | Tavneos, Parsabiv, Aranesp |
| Veloxis Pharmaceuticals, INC. | $180.38 | 2020-2023 | Envarsus |
| Bayer Healthcare Pharmaceuticals INC. | $159.02 | 2021-2023 | |
| Opko Pharmaceuticals, LLC | $153.38 | 2019-2023 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $146.10 | 2022-2024 | Acthar |
| Horizon Therapeutics Plc | $117.51 | 2021-2023 | Krystexxa |
| Daiichi Sankyo INC. | $109.91 | 2019-2023 | Injectafer |
| Travere Therapeutics, INC. | $109.73 | 2022-2024 | |
| Mallinckrodt Enterprises LLC | $82.56 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $74.95 | 2021-2023 | Lupkynis |
| Calliditas Therapeutics US INC. | $43.64 | 2022-2023 | Tarpeyo |
| Novo Nordisk INC | $22.13 | 2024 | Rybelsus, Ozempic |
| Amag Pharmaceuticals, INC. | $20.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Noble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.